Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

NCT ID: NCT01226056

Last Updated: 2010-10-21

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-03-31
• Study Completion Date: 2012-12-31

Brief Summary

Sorafenib is an oral multikinase inhibitor and among its targets are several RTKs involved in tumor genesis (Raf, Flt-3, c-Kit and RET) and angiogenesis (VEGFR1, 2 and 3 and PDGFRß). Therefore sorafenib inhibits tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling.

RAD001 is a novel derivative of rapamycin. It selectively inhibits mTOR directly blocking tumor cells by preventing tumor cell growth and proliferation and indirectly by inhibiting angiogenesis (via potent inhibition of the HIF-1 and consequently VEGF production).

Targeting mTOR in combination with sorafenib might lead to more profound effects on tumor cell biology than could be achieved through individual targeting of some proteins.

New drugs have often met only limited success since not always target pathways responsible for tumor development and growth are targeted. To overcome this problem, the specific pathways targeted by the investigators two drugs will be analyzed in each single patient before the inclusion.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RAD001 in combination with sorafenib

Group Type: EXPERIMENTAL

RAD001 in combination with sorafenib

Intervention Type: DRUG

Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.

The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).

Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.

Interventions

RAD001 in combination with sorafenib

Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.

The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).

Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.

Intervention Type: DRUG

Other Intervention Names

RAD001 (Everolimus); Sorafenib (Nexavar®)

Eligibility Criteria

Inclusion Criteria

1. Patients with progressive disease of advanced solid tumours judged non suitable for standard treatment

2. Biopsiable lesion or archive tissue not older than 1 year to assess the expression of:

• phosphorylated AKT
• phosphorylated p70S6
• RKIP (Raf Kinase Inhibitor Protein)
• phosphorylated ERK1/2 The presence of at least one of the previous targets will be mandatory for patient enrolment

3. At least 1 uni-dimensional measurable lesion according to modified RECIST

4. Life expectancy of at least 12 weeks

5. Age ≥ 18 years old

6. ECOG Performance Status of 0 or 1

7. Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:

• Haemoglobin ≥9.0 g/dL (5.6 mmol/L)
• Absolute neutrophil count (ANC)≥1.5 x 109/L
• Platelet count ≥100 x 109/L
• Total bilirubin ≤1.5 x upper limit of normal (ULN)
• ALT and AST ≤2.5 x ULN (≤5 x ULN for patients with liver involvement of their cancer)
• Alkaline phosphatase ≤4 x ULN
• PT-INR/PTT <1.5 x ULN
• Serum albumin levels ≥2.5 mg/dl
• Serum creatinine ≤1.5 x ULN

8. HBV/HCV testing in the 2 weeks before treatment start in specific categories of patient with hepatitis B and C risk factors and in additional patients at the discretion of the investigators according to guidelines in Appendix 6.

9. All fertile patients must use adequate contraception while on study and for three subsequent months

10. Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures

Exclusion Criteria

1. History of cardiac disease: congestive heart failure (NYHA II-IV), active coronary artery disease - CAD (MI more than 6 months prior to study entry is allowed), cardiac arrhythmias requiring antiarrhythmic therapy (betablockers or digoxin are permitted) or uncontrolled hypertension

2. History of HIV infection or chronic hepatitis B or C

3. Patients with NSCLC squamous histotype

4. Recurrent hemoptysis or cerebrovascular accident within 12 months, or peripheral vascular disease with claudication on less than 1 block (about 150 metres), or history of clinically significant bleeding non-traumatic

5. Deep venous thrombosis or pulmonary embolus within 1 year or ongoing need for full-dose oral or parenteral anticoagulation

6. Clinically active infections (> Grade 2 NCI-CTC AE version 3.0)

7. Evidence of CNS tumor metastases

8. History of organ allograft

9. Pre-existing thyroid abnormality where thyroid function cannot be maintained in the normal range by medication

10. Serious, non-healing wound, ulcer, or bone fracture

11. Second malignancies within the past 5 years (except for non - melanoma skin cancer and cervical carcinoma in situ)

12. Pregnant or breast-feeding patients

13. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

14. Any condition that is unstable or could jeopardize the safety of the patient and his/her compliance in the study

15. Patients unable to swallow oral medications

16. Any malabsorption condition

17. Prior treatment with sorafenib or m-TOR inhibitors

18. Ongoing requirement for systemic corticosteroid medication or other immunosuppressants

19. Radiotherapy within 3 weeks of start of study drug. Palliative radiotherapy is allowed. Major surgery within 4 weeks of study entry

20. Radiotherapy involving > 30% of the active bone marrow

21. Autologous bone marrow transplant or stem cell rescue within 4 months of study entry

22. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or planned during the study period

23. Investigational drug therapy outside of this trial during or within 4 weeks of study entry

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

Bayer

INDUSTRY

Sponsor Role: collaborator

Southern Europe New Drug Organization

OTHER

Sponsor Role: lead

Responsible Party

SENDO

Principal Investigators

filippo De Braud, MD

Role: STUDY_CHAIR

IEO, Milano (Italy)

Locations

Istituto Europeo di Oncologia,

Milan, , Italy

Countries

Italy

Other Identifiers

S075SORD01

Identifier Type: -

Identifier Source: org_study_id